SuperworthResMed EPS RMD
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $10.43
- Latest quarter, Q4 FY26
- $2.64
- +2% on a year earlier
- Fiscal year 2026
- $10.43
- +10% on the year before
ResMed's earnings per share was $10.43 over the twelve months to Jun 30, 2026, up 10% on a year earlier.
In its latest quarter, Q4 FY26, it was $2.64, up 2% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 26% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $10.43 | +10% |
| FY2025 | $9.51 | +37% |
| FY2024 | $6.93 | +14% |
| FY2023 | $6.10 | +15% |
| FY2022 | $5.31 | +64% |
| FY2021 | $3.24 | −24% |
| FY2020 | $4.27 | +53% |
| FY2019 | $2.79 | +27% |
| FY2018 | $2.19 | −9% |
| FY2017 | $2.41 | −3% |
| FY2016 | $2.49 | +1% |
| FY2015 | $2.47 | +3% |
| FY2014 | $2.40 | +14% |
| FY2013 | $2.10 | +22% |
| FY2012 | $1.72 | +19% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $2.64 | +2% | $10.43 | |
| Q3 FY26 | $2.74 | +10% | $10.37 | |
| Q2 FY26 | $2.68 | +15% | $10.11 | |
| Q1 FY26 | $2.37 | +12% | $9.77 | |
| Q4 FY25 | $2.58 | +30% | $9.51 | |
| Q3 FY25 | $2.48 | +22% | $8.91 | |
| Q2 FY25 | $2.34 | +65% | $8.47 | |
| Q1 FY25 | $2.11 | +42% | $7.55 | |
| Q4 FY24 | $1.98 | +27% | $6.93 | |
| Q3 FY24 | $2.04 | +29% | $6.51 | |
| Q2 FY24 | $1.42 | −7% | $6.05 | |
| Q1 FY24 | $1.49 | +4% | $6.16 |
Against its peers
Companies in Medical - Instruments & Supplies nearest ResMed's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RMDResMed | $10.43 | +10% a year |
| MDLNMedline | n/m | |
| WSTWest Pharmaceutical Services | $7.81 | +17% a year |
| BDXBecton, Dickinson and | $3.31 | −40% a year |
| SOLVSolventum | $8.18 | +277% a year |
| PENPenumbra | $4.07 | +8% a year |
| COOCooper Companies | $2.93 | +44% a year |
| ALGNAlign Technology | $5.75 | −3% a year |
| GMEDGlobus Medical | $3.91 | +50% a year |
| PODDInsulet | $5.35 | +64% a year |
| ISRGIntuitive Surgical | $8.27 | +9% a year |
| Peer median | $5.35 |
Where ResMed ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on ResMed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.